Burfiralimab

Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies[1].

Product Specifications

CAS Number

[2460809-80-5]

Product Name Alternative

HzVSF-v13

UNSPSC

12352203

Target

Interleukin Related; SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/burfiralimab.html

Purity

95.20

Solubility

10 mM in DMSO

Smiles

[Burfiralimab]

Molecular Weight

(144.6 kDa)

References & Citations

[1]Prasenohadi Prasenohadi, et al. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. J Clin Med. 2022 May 24;11 (11) :2961.